Design Therapeutics, Inc. (DSGN)
NASDAQ: DSGN · Real-Time Price · USD
9.37
-0.04 (-0.43%)
At close: Nov 26, 2025, 4:00 PM EST
9.19
-0.18 (-1.92%)
After-hours: Nov 26, 2025, 4:16 PM EST
Design Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Design Therapeutics stock has a target of 13, which predicts a 38.74% increase from the current stock price of 9.37.
Price Target: $13 (+38.74%)
Analyst Consensus: Buy
Analyst Ratings
According to 1 stock analyst, the rating for Design Therapeutics is "Buy". This means that the analyst believes this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 3 | 3 | 3 | 3 | 3 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Hold → Buy Upgrades $6 → $13 | Hold → Buy | Upgrades | $6 → $13 | +38.74% | Nov 20, 2025 |
| RBC Capital | RBC Capital | Hold Maintains $5 → $6 | Hold | Maintains | $5 → $6 | -35.97% | Nov 6, 2025 |
| RBC Capital | RBC Capital | Hold Reiterates $4 | Hold | Reiterates | $4 | -57.31% | Aug 6, 2024 |
| Piper Sandler | Piper Sandler | Hold → Buy Upgrades $6 → $12 | Hold → Buy | Upgrades | $6 → $12 | +28.07% | May 7, 2024 |
| RBC Capital | RBC Capital | Hold Reiterates $4 | Hold | Reiterates | $4 | -57.31% | Mar 20, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.36
from -0.88
EPS Next Year
-1.24
from -1.36
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | n/a | |||
| Avg | n/a | n/a | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.37 | -0.86 | |||
| Avg | -1.36 | -1.24 | |||
| Low | -1.33 | -1.42 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.